论文信息 - Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization - 字舞流文

Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization

J. Benichou | P. Reix | I. Pin | I. Fajac | A. Munck | L. Mély | C. Marguet | C. Belleguic | D. Grenet | P. Vigneron | M. Laurans | R. Chiron | F. Chédevergne | K. Chandarana | D. Hubert | C. Payen-Champenois | N. Remus | C. Desouza | S. Ramel | N. Wizla | N. Kinnman | I. Danner-Boucher | J. Languepin | N. Dufeu | Sophie Philippe Veronique Natacha Laurence Bassinet Isabe Ramel Vigneron Storni Remus Durieu Laurans | V. Storni | Laurence Bassinet Isabelle Durieu | Cinthia Rames Françoise Troussier | Marie-Laure Dalphin Frédéric Huet | Boubou Camara Annabelle Payet | Marc Albertini Julie Mankikian | L. Cosson | Eric Deneuville Marie Mittaine | Valérie David | Thierry Langin Stéphanie Bui | N. Rémus

[1] S. Rowe,et al. Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation. , 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[2] E. Haseltine,et al. Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial , 2020, American journal of respiratory and critical care medicine.

[3] C. Castellani,et al. From Ivacaftor to Triple Combination: A Systematic Review of Efficacy and Safety of CFTR Modulators in People with Cystic Fibrosis , 2020, International journal of molecular sciences.

[4] L. Hoffman,et al. Pseudomonas aeruginosa and Staphylococcus aureus during respiratory infections ? , 2019 .

[5] M. Rosenfeld,et al. Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. , 2018, The Lancet. Respiratory medicine.

[6] K. Klein,et al. A systematic review of studies examining the rate of lung function decline in patients with cystic fibrosis. , 2016, Paediatric respiratory reviews.

[7] D. Jayne,et al. SUMMARY OF PRODUCT CHARACTERISTICS , 2014 .

[8] W. T. Harris,et al. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. , 2016, The Lancet. Respiratory medicine.

[9] S. McColley,et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial. , 2015, The Lancet. Respiratory medicine.

[10] P. Hiatt,et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. , 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[11] Ying Jiang,et al. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). , 2014, The Lancet. Respiratory medicine.

[12] Umer Khan,et al. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. , 2014, American journal of respiratory and critical care medicine.

[13] P. Lee,et al. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial. , 2013, The Lancet. Respiratory medicine.

[14] J. Mainz,et al. Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. , 2013, American journal of respiratory and critical care medicine.

[15] H. Quinton,et al. Better nutritional status in early childhood is associated with improved clinical outcomes and survival in patients with cystic fibrosis. , 2013, The Journal of pediatrics.

[16] S. Stanojevic,et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations , 2012, European Respiratory Journal.

[17] F. van Goor,et al. Ivacaftor potentiation of multiple CFTR channels with gating mutations. , 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[18] Matthias Griese,et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. , 2011, The New England journal of medicine.

[19] J. Geddes,et al. What is a randomised controlled trial? , 2009, Epidemiologia e Psichiatria Sociale.

[20] P. Negulescu,et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770 , 2009, Proceedings of the National Academy of Sciences.

[21] J. Elborn,et al. Nutrition in adults with cystic fibrosis. , 1998, Clinical nutrition.

[22] A. Munck,et al. Retrospective observational study of French patients with cystic fibrosis and a Gly551Asp-CFTR mutation after 1 and 2years of treatment with ivacaftor in a real-world setting. , 2018, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[23] F. van Goor,et al. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. , 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.